Results 181 to 190 of about 110,311 (309)

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

open access: yesAdvanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave   +8 more
wiley   +1 more source

Cytomegalovirus Infection in an Extremely Preterm Infant: A Diagnostic Challenge. [PDF]

open access: yesCureus
Valiente-Rodriguez P   +4 more
europepmc   +1 more source

Spatially Controlled Embedded Bioprinting of Prevascularized Spheroids‐Containing Biopatch Enables Functional Skin Regeneration

open access: yesAdvanced Healthcare Materials, EarlyView.
A spatially controlled embedded bioprinting strategy enables precise engineering of prevascularized multicellular spheroids within skin‐derived dECM bioinks. Optimized spheroid size, composition, and spacing promote vascular maturation, paracrine signaling, and tissue integration, resulting in enhanced angiogenesis, blood perfusion, and functional skin
Minjun Ahn   +6 more
wiley   +1 more source

Biphasic Co‐Delivery of Curcumin and 5‐FU using 3D‐Printed Dissolving Microneedles for Skin Cancer Therapy

open access: yesAdvanced Healthcare Materials, EarlyView.
Using pixel‐aware digital light processing, the authors created high‐resolution, dissolvable microneedles from a PEGDA/VP matrix. These microneedles encapsulate curcumin and 5‐fluorouracil and dissolve in the skin, co‐delivering drugs directly to tumours.
Rutuja N. Meshram, Dimitrios A. Lamprou
wiley   +1 more source

Structural and Functional Abnormalities in the Preterm Heart: From Development to Adulthood. [PDF]

open access: yesJ Am Heart Assoc
Zegelbone P   +5 more
europepmc   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

open access: yesAdvanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy